The results suggested that three doses of nivolumab (0.3, 2, 10 mg/kg) demonstrated controllable and healthy anti-tumor activity in patients who had been pre-treated with VEGF-targeted drugs. The gene discussed is VEGFA; the disease is neoplasm.